NKIRAS1 is an atypical Ras-like protein that functions as a potent negative regulator of NF-κB signaling, a critical pathway in both normal cellular processes and tumorigenesis. The protein inhibits canonical NF-κB activation by preventing phosphorylation and degradation of NFKBIB (IκB), the NF-κB inhibitor, while also mediating cytoplasmic retention of the p65/RELA NF-κB subunit 1. This dual mechanism operates independently of classical GTPase activity, as both GTP- and GDP-bound NKIRAS1 forms suppress NF-κB phosphorylation. In cancer biology, NKIRAS1 acts as a tumor suppressor with broad relevance across malignancies. Reduced NKIRAS1 expression is associated with worse prognosis in multiple cancer types, particularly those lacking oncogenic RAS mutations 1. In renal cell carcinoma, NKIRAS1 expression is downregulated in 75% of tumors, with hemizygous deletions occurring in 64% of clear cell RCC samples; higher-grade tumors show lower NKIRAS1 expression 2. In lung cancer, NKIRAS1 upregulation correlates with loss of promoter methylation and methylation of regulatory microRNAs, suggesting epigenetic control 3. Clinically, NKIRAS1 emerges as a significant hub gene in kidney disease pathways. It functions as a key regulatory gene in APOL1-associated nephropathies and demonstrates correlation with inflammatory signaling and mitochondrial gene regulation in focal segmental glomerulosclerosis 45. Genetic variants affecting NKIRAS1 expression are linked to chr3 kidney disease risk through inflammation-associated pathways 6. Additionally, NKIRAS1 methylation patterns contribute to post-infectious respiratory morbidity phenotypes following RSV infection 7.